No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation

European Journal of Clinical Pharmacology

Volumn 65, Issue 10, 2009, Pages 1047-1053

  Miura, Masatomo ^a   Satoh, Shigeru ^b   Kagaya, Hideaki ^a   Saito, Mitsuru ^b   Inoue, Takamitsu ^b   Tsuchiya, Norihiko ^b   Suzuki, Toshio ^a   Habuchi, Tomonori ^b  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Age; CYP3A5; Elderly; Mycophenolic acid; Pharmacogenetics; Prednisolone; Tacrolimus

Indexed keywords

BASILIXIMAB; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGING; ALLELE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGING; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BODY WEIGHT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; TIME FACTORS;

EID: 70349243452     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0721-9     Document Type: Article

References (30)

1. KJ Jager PC van Dijk FW Dekker B Stengel K Simpson JD Briggs ERA-EDTA Registry Committee 2003 The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes Clin Nephrol 60 352 360 14640241 1:STN:280:DC%2BD3srlvFOktw%3D%3D
2. GM Danovitch J Gill S Bunnapradist 2007 Immunosuppression of the elderly kidney transplant recipients Transplantation 84 285 291 17700150 10.1097/01.tp.0000275423.69689.dc (Pubitemid 47258313)
3. S Nakai I Masakane T Akiba K Iseki Y Watanabe N Itami N Kimata T Shigematsu T Shinoda T Syoji T Syoji K Suzuki K Tsuchida H Nakamoto T Hamano S Marubayashi O Morita K Morozumi K Yamagata A Yamashita K Wakai A Wada Y Tsubakihara 2007 Overview of regular dialysis treatment in Japan (as of 31 December 2005) Ther Apher Dial 11 411 441 18028170 10.1111/j.1744-9987.2007. 00523.x (Pubitemid 350135366)
4. G Marchesini V Bua A Brunori G Bianchi P Pisi A Fabbri M Zoli E Pisi 1988 Galactose elimination capacity and liver volume in aging man Hepatology 8 1079 1083 3417228 10.1002/hep.1840080516 1:CAS:528:DyaL1cXlvVOru7Y%3D (Pubitemid 18236606)
5. KW Woodhouse HA Wynne 1988 Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly Clin Pharmacokinet 15 287 294 3203484 10.2165/00003088-198815050-00002 1:STN:280: DyaL1M%2FnslOksg%3D%3D
6. HA Wynne E Cope E Mutch MD Rawlins KW Woodhouse OF James 1989 The effect of age upon liver volume and apparent liver blood flow in healthy man Hepatology 9 297 301 2643548 10.1002/hep.1840090222 1:STN:280:DyaL1M7gvVejuw%3D%3D (Pubitemid 19063317)
7. EA Sotaniemi AJ Arranto O Pelkonen M Pasanen 1997 Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions Clin Pharmacol Ther 61 331 339 9091249 10.1016/S0009-9236(97)90166-1 1:CAS:528:DyaK2sXitlKks7c%3D (Pubitemid 27145435)
8. G Ginsberg D Hattis A Russ B Sonawane 2005 Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals Environ Health Perspect 113 1243 1249 16140636 1:CAS:528:DC%2BD2MXht1agu7nI
9. A Lampen U Christians FP Guengerich PB Watkins JC Kolars A Bader AK Gonschior H Dralle I Hackbarth KF Sewing 1995 Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability Drug Metab Dispos 23 1315 1324 8689938 1:CAS:528:DyaK28XhvF2gtA%3D%3D
10. L Pichard I Fabre M Daujat J Domergue H Joyeux P Maurel 1992 Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes Mol Pharmacol 41 1047 1055 1614409 1:CAS:528:DyaK38Xls1Citrk%3D
11. E Hustert M Haberl O Burk R Wolbold YQ He K Klein AC Nuessler P Neuhaus J Klattig R Eiselt I Koch A Zibat J Brockmoller JR Halpert UM Zanger L Wojnowski 2001 The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 773 779 11740341 10.1097/00008571-200112000-00005 1:CAS:528:DC%2BD38XnsFKqsrk%3D (Pubitemid 33151512)
12. N Tsuchiya S Satoh H Tada Z Li C Ohyama K Sato T Suzuki T Habuchi T Kato 2004 Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 1182 1187 15502717 10.1097/01.TP.0000137789.58694.B4 1:CAS:528:DC%2BD2cXovVGisL8%3D (Pubitemid 39426437)
13. H Tada N Tsuchida S Satoh H Kagaya Z Li K Satoh M Miura T Suzuki T Kato T Habuchi 2005 Impact of CYP3A5 and MDR1(ABCB1)C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 1730 1732 15919447 10.1016/j.transproceed.2005.02.073 1:CAS:528: DC%2BD2MXks1Crs78%3D (Pubitemid 40790812)
14. M Miura S Satoh K Inoue H Kagaya M Saito T Inoue T Habuchi T Suzuki 2008 Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients Steroids 73 1052 1059 18502461 10.1016/j.steroids.2008.04.002 1:CAS:528:DC%2BD1cXosVOntr0%3D
15. RE Bullingham AJ Nicholls BR Kamm 1998 Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 429 455 9646007 10.2165/00003088- 199834060-00002 1:CAS:528:DyaK1cXkt1eisro%3D (Pubitemid 28273453)
16. LM Shaw DW Holt M Oellerich B Meiser T van Gelder 2001 Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion Ther Drug Monit 23 305 315 11477311 10.1097/00007691-200108000-00001 1:CAS:528:DC%2BD3MXmtFGnsrk%3D (Pubitemid 32708913)
17. DW Holt 2002 Monitoring mycophenolic acid Ann Clin Biochem 39 173 183 12038590 10.1258/0004563021902035 1:CAS:528:DC%2BD38XkslCqsLg%3D (Pubitemid 34494205)
18. M Mourad P Wallemacq J Konig EH de Frahan DC Eddour M De Meyer J Malaise JP Squifflet 2002 Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet 41 319 327 12036390 10.2165/00003088-200241050-00001 1:CAS:528:DC%2BD38Xlt1Gjtbk%3D
19. HL Liston JS Markowitz CL DeVane 2001 Drug glucuronidation in clinical psychopharmacology J Clin Psychopharmacol 21 500 515 11593076 10.1097/00004714-200110000-00008 1:CAS:528:DC%2BD3MXnslSlsrw%3D (Pubitemid 32937433)
20. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 10.1159/000180580 1:STN:280: DyaE28%2FnsF2isw%3D%3D
21. S Fukuen T Fukuda H Maune Y Ikenaga I Yamamoto T Inaba J Azuma 2002 Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population Pharmacogenetics 12 331 334 12042671 10.1097/00008571-200206000-00009 1:CAS:528:DC%2BD38XnsFKqsr8%3D (Pubitemid 34620661)
22. H Kagaya K Inoue M Miura S Satoh M Saito H Tada T Habuchi T Suzuki 2006 Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients Yakugaku Zasshi 126 1357 1362 17139160 10.1248/yakushi.126.1357 1:CAS:528:DC%2BD2sXot1eqtQ%3D%3D (Pubitemid 46089896)
23. M Miura H Kagaya S Satoh K Inoue M Saito T Habuchi T Suzuki 2008 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic-glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients Ther Drug Monit 30 559 564 10.1097/FTD.0b013e3181838063 1:CAS:528:DC%2BD1cXht1aisLzP
24. CE Staatz SE Tett 2005 Pharmacokinetic considerations relating to tacrolimus dosing in the elderly Drug Aging 22 541 557 10.2165/00002512- 200522070-00001 1:CAS:528:DC%2BD2MXhtVCjtbrK (Pubitemid 41214548)
25. M Mourad P Wallemacq M De Meyer S Brandt V Van Kerhove J Malaise D Chaib Eddour D Linson V Haufroid 2006 The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function Clin Chem Lab Med 44 1192 1198 17032130 10.1515/CCLM.2006.229 1:CAS:528:DC%2BD28XhtFyms7zF (Pubitemid 44580800)
26. J Kovarik EU Koelle 1999 Cyclosporin pharmacokinetics in the elderly Drug Aging 15 197 205 10.2165/00002512-199915030-00003 1:CAS:528:DyaK1MXmsFSjs7o%3D (Pubitemid 29438139)
27. CX Wang FH Meng LZ Chen B Ren SX Li JG Fei J Qiu SX Deng J Li SY Chen 2007 Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients Transplant Proc 39 1392 1395 17580146 10.1016/j. transproceed.2007.02.082 1:CAS:528:DC%2BD2sXmsFygtb8%3D (Pubitemid 46907916)
28. O Bernard C Guillemette 2004 The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants Drug Metab Dispos 32 775 778 15258099 10.1124/dmd.32.8.775 1:CAS:528: DC%2BD2cXmtFCjt74%3D (Pubitemid 38955603)
29. RE Bullingham A Nicholls M Hale 1996 Pharmacokinetics of mycophenolate mofetil (RS61443): a short review Transplant Proc 28 925 929 8623466 1:CAS:528:DyaK28XjtVGlsbo%3D
30. R Bullingham S Monroe A Nicholls M Hale 1996 Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration J Clin Pharmacol 36 315 324 8728345 1:CAS:528:DyaK28XjtV2isrg%3D